I have watched the same pattern repeat in clinical practice for years. A patient has completed two or three courses of topical or oral antibiotics. Their acne is not cleared. The next practitioner moves to a different antibiotic in the rotation. Nothing improves.
The answer, in most of these cases, is resistance. Cutibacterium acnes has developed tolerance to the antibiotic being used, and repeating the prescription compounds the problem rather than solving it.
This is not a peripheral concern for aesthetic practitioners. It affects clinical outcomes. It exposes practitioners to professional risk. And it contributes to a public health priority that the Department of Health and Social Care placed at the top of the national agenda through the 2024 to 2029 Antimicrobial Resistance Action Plan.
What NICE Guidance Requires
The NICE Clinical Knowledge Summary on acne vulgaris is explicit on antibiotics. Topical antibiotics should be used in combination with benzoyl peroxide, not as monotherapy, because benzoyl peroxide reduces the emergence of resistant Cutibacterium acnes strains. Topical antibiotic courses should be limited to a maximum of 12 weeks. Oral antibiotics should not be used for maintenance once initial control has been achieved.
Many practitioners are not following this. Some prescribe topical antibiotics without benzoyl peroxide. Some continue courses well beyond 12 weeks. Some prescribe for maintenance without a clear plan to transition off.
In primary care, these decisions carry audit trails and oversight mechanisms. In aesthetic practice, accountability is more diffuse. That makes the individual practitioner's responsibility to know the guidance more significant, not less.
Resistance, the Microbiome, and What the Evidence Shows
Cutibacterium acnes is a commensal organism. It lives in healthy skin and acne-affected skin alike. What drives acne is not its presence, but the conditions that allow inflammatory phylotypes to proliferate: disrupted barrier function, excess sebum, and the anaerobic follicular environment that forms when follicles are blocked.
Broad antibiotic use disrupts the entire skin microbiome, not only acne-driving strains. Organisms that compete with pathogenic Cutibacterium acnes populations are removed alongside them. Over repeated courses, resistant strains survive and establish dominance. European studies from the past decade have found antibiotic-resistant Cutibacterium acnes in more than half of acne patients studied. UK practitioners and patients are part of that picture.
When a patient presents with acne that has failed multiple antibiotic courses, the clinical question is not which antibiotic to try next. It is whether resistance has already made that category of treatment ineffective for this patient.
The Consultation Question for Aesthetic Practitioners
Most aesthetic practitioners are not the primary prescriber for their acne patients. Many patients arrive at an aesthetic clinic while concurrently managing acne under a GP or dermatology prescription.
Asking about current prescriptions is part of a safe aesthetic consultation. If a patient is on a topical antibiotic and you add professional chemical exfoliation or a treatment series on top, you are altering the skin environment in ways that interact with both the treatment mechanism and the microbiome's stability.
A patient on long-term topical clindamycin without benzoyl peroxide is a patient whose skin may already carry resistant strains. Knowing that changes how you approach barrier management, treatment sequencing, and referral decisions.
A Stewardship-Aware Approach in Practice
For practitioners who prescribe, stewardship means three practical changes.
First, topical antibiotics combined with benzoyl peroxide from the outset of treatment. The evidence for this combination in reducing resistance is established and the guidance is explicit. Monotherapy is not in line with current UK recommendations.
Second, a set 12-week maximum for topical antibiotic courses, agreed with the patient at the start of treatment rather than extended indefinitely because the patient is tolerating it.
Third, a transition plan for what comes after. If antibiotics achieve clearance, the maintenance approach matters. Topical retinoids are the evidence-based maintenance option. They address comedone formation, reduce follicular hyperkeratinisation, and carry no resistance risk.
For patients who cycle through antibiotics without resolution, the correct clinical step is reassessment rather than repetition. GP or dermatology referral for isotretinoin consideration is a legitimate pathway when antibiotics have repeatedly failed. The aesthetic practitioner's role is to identify that point and act on it, not to continue prescribing in the same category.
Putting the Guidance Into Practice
Antibiotic stewardship in acne is not an abstract concern. It affects the patients in your clinic today, the outcomes they experience over the next 12 months, and your professional standing as someone who prescribes or co-manages treatment.
The NICE Clinical Knowledge Summary is available and free to access. The national AMR commitment is government policy. Following the evidence in acne is as much a professional responsibility as any other aspect of clinical practice.
If you want a structured clinical framework for acne assessment, treatment planning, and microbiome-aware protocols that align with UK guidance, Aesthetics Unlocked's Acne Decoded covers the full consultation model at aestheticsunlocked.co.uk/courses/acne-decoded.